Weight-loss and diabetes jabs and your mood: what a big review found
What happened
A review published on 6 September 2026 looked at whether GLP-1 medicines affect people's mental health. GLP-1 medicines are the group that includes semaglutide and similar drugs. They are used for type 2 diabetes and for weight management. Millions of people now take them. A few years ago, safety regulators started asking a difficult question. Some people taking these medicines had reported low mood or thoughts of self-harm. Regulators in Europe and the United States reviewed the evidence and did not find proof of a link. But the question kept coming back, and researchers kept studying it. This new review, published in the journal Cureus by Quadir and colleagues, pulled together 11 studies. Ten were cohort studies, which follow groups of people over time. One was a cross-sectional study, which takes a single snapshot. Between them they covered more than 4.9 million patients. The headline finding was reassuring. Nine of the ten cohort studies found no increase in mental health risk, or found the opposite: a small protective effect.
Why this matters
If you take one of these medicines, or you are thinking about it, this is the sort of question you want a straight answer to. Worry about a medicine is not a small thing. It can stop people starting a treatment that would help them. It can also make people stop suddenly, which brings its own risks, especially with diabetes. There is a second reason this matters. Depression and anxiety are more common in people living with type 2 diabetes and in people living with obesity than in the general population. So if you look at a group of people on these medicines and find more depression, you have to ask a hard question: is the medicine causing it, or was it already more likely in that group? Sorting out that difference is exactly what good research tries to do, and exactly where it gets difficult.
What the evidence actually says
Let us be precise about what this review can and cannot tell us. The encouraging findings first. One large multinational registry study found people using GLP-1 medicines had around a 17% lower risk of suicide death and non-fatal self-harm than comparison groups. Another large study reported about a 10% lower risk of suicidal thoughts, attempts or intentional self-harm. In studies that used proper mood questionnaires, people on semaglutide scored modestly lower for depression and anxiety. Now the finding that did not fit. One study, in people being treated for obesity rather than diabetes, reported nearly three times the risk of major depressive disorder, and about double the risk of anxiety and suicidal thoughts. The review's authors flagged this as a genuine outlier that needs explaining rather than ignoring. And here are the limits, which the authors state plainly. Every study included was observational. That means researchers watched what happened; they did not randomly assign people to treatments. Observational studies can show that two things go together. They cannot prove one caused the other. There were no randomised controlled trials in the review that had mental health as their main outcome. Only one study used validated mood scales. And there may be 'surveillance bias': people being treated for obesity are often monitored more closely, so problems are more likely to be spotted and recorded, which can make rates look higher. It is also worth knowing that Cureus is a general medical journal, not a specialist psychiatry title. That does not make the review wrong. It does mean this should be read as one useful piece of evidence, not the final word. So the fair summary: across nearly five million patients, there is no clear sign that GLP-1 medicines worsen mental health overall, and some hints they may help. But the evidence is not the strongest kind, and one study pointed the other way.
Practical advice
If you take a GLP-1 medicine, do not stop it because of a headline. Stopping suddenly can affect your blood sugar control and your overall treatment plan. Speak to your prescriber first. Do tell someone if your mood changes. New or worsening low mood, anxiety, or any thoughts of harming yourself are always worth reporting, whatever medicine you are on. Tell your GP, your pharmacist or your diabetes team. You will not be wasting their time. If you have a history of depression, anxiety or self-harm, say so before you start. That is not a reason you cannot have the medicine. It is a reason for your team to keep a closer eye on you. You can report a suspected side effect yourself through the MHRA's Yellow Card scheme at yellowcard.mhra.gov.uk. Reports from patients genuinely feed into safety monitoring. If you are struggling right now, do not wait. Call 111, contact your GP, or ring Samaritans free on 116 123, any time of day or night. And be careful where you get these medicines. Buying weight-loss injections from unregulated online sellers means you have no prescriber checking whether they are right for you, and no one monitoring you afterwards.
What to know
A review published on 6 September 2026 pooled 11 studies covering more than 4.9 million patients taking GLP-1 medicines. Nine of the ten cohort studies found no increase in mental health risk, and some found lower rates of self-harm and suicidal thoughts. One study in people treated for obesity found the opposite, with markedly higher rates of depression and anxiety. All the studies were observational, so they cannot prove cause and effect. There were no randomised trials designed to answer this question. The practical message has not changed: these medicines are not known to worsen mental health for most people, but any change in your mood is worth reporting, and you should never stop a prescribed medicine without speaking to your prescriber. Sources: News-Medical, 'GLP-1 drugs appear psychiatrically safe, but one finding still raises questions', 6 September 2026, https://www.news-medical.net/news/20260906/GLP-1-drugs-appear-psychiatrically-safe-but-one-finding-still-raises-questions.aspx ; Quadir A and colleagues, 'Neuropsychiatric outcomes with GLP-1 receptor agonists: a systematic review', Cureus, 2026;18(9), DOI 10.7759/cureus.115703, https://doi.org/10.7759/cureus.115703 ; MHRA Yellow Card scheme, accessed 7 September 2026, https://yellowcard.mhra.gov.uk This article is for general information and does not replace advice from a doctor, pharmacist or other qualified healthcare professional. Never stop or change a prescribed medicine without speaking to your prescriber first.
Related articles
Free finger-prick kits that tell you your blood type
NHS Blood and Transplant has started giving away free kits that let you find out your own blood type at home. The scheme was announced on 2 September 2026. Up…
The shingles jab and your heart: what new research found
New research suggests the modern shingles vaccine may do more than prevent shingles. It may also be linked to less heart disease. The study was published in th…
A common prostate and ED medicine is linked to higher glaucoma risk
A large study has linked long-term use of the medicine tadalafil to a higher chance of developing glaucoma, an eye condition that can steal your sight without w…